乳腺癌微环境中趋化因子CCL20作用的研究进展

doi:10.11904/j.issn.1002-3070.2022.03.010

Abstract

Abstract: Chemokines are a class of low molecular weight cytokines,which play an important role in regulating the tumor microenvironment.Chemokines in the tumor microenvironment can not only trend chemotactic leukocytes,but also induce nearby respond cells to affect tumor growth,invasion,metastasis and angiogenesis.Chemokines are closely related to the occurrence and development of inflammation diseases and tumors.Among them,chemokine CCL20 in the CC family plays an important role in the invasion and metastasis of various malignant tumors.In recent years,it has been found that the chemokine CCL20 plays an important regulatory role in breast cancer immunosuppression,angiogenesis,induction of epithelial-mesenchymal transition,tumor invasion and metastasis.However,the mechanism of CCL20 action in breast cancer is not fully understood.This article focuses on the function of CCL20,a member of the chemokine CC subfamily,in the breast cancer microenvironment,and discusses the relationship between CCL20 and the breast cancer microenvironment,in order to provide new ideas for breast cancer targeted therapy.

Key words: Tumor microenvironment, Chemokine, CCL20, Breast cancer

CLC Number:

R737.9

LIU Xinxin, YAO Xinhui, SUN Yuefeng, MIU Meiqi, CHEN Jing. Research progress in the role of chemokine CCL20 in breast cancer microenvironment[J]. Journal of Practical Oncology, 2022, 36(3): 250-254.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.03.010

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I3/250

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Chen KL,Li L,Yang FX,et al.SIRT7 depletion inhibits cell proliferation,migration,and increases drug sensitivity by activating p38MAPK in breast cancer cells[J].J Cell Physiol,2018,233(9):6767-6778.
3 Silva P,Borges BC,Uehara IA,et al.Chemokines and the extracellular matrix:set of targets for tumor development and treatment[J].Cytokine,2021(42):155548.
4 Furue K,Ito T,Tsuji G,et al.The CCL20 and CCR6 axis in psoriasis[J].Scand J Immunol,2020,91(3):e12846.
5 袁思敏,杨勇,王雪莹,等.CCL20-CCR6轴与上皮-间质转化在乳腺癌中的研究进展[J].国际外科学杂志,2021,48(6):401-405.
6 唐妍,张梦梅,王菲,等.肿瘤微环境中的各组成成分在肿瘤发生、发展中的作用[J].中国医药导报,2018,15(6):39-43.
7 何嘉慧,王熙才,王佶,等.肿瘤微环境与乳腺癌细胞糖代谢重编程研究进展[J].肿瘤学杂志,2021,27(5):359-363.
8 封贺,王建莉,路小超,等.肿瘤相关巨噬细胞的研究进展[J].生命科学,2019,31(3):217-224.
9 杨云松,江一舟,胡欣,等.乳腺肿瘤微环境靶向治疗的研究进展[J].中国癌症杂志,2019,29(12):977-984.
10 Zhang H,Chen K,Tan Q,et al.Structural basis for chemokine recognition and receptor activation of chemokine receptor CCR5[J].Nat Commun,2021,12(1):1-12.
11 Aravind A,Palollathil A,Rex DAB,et al.A multi-cellular molecular signaling and functional network map of C-C motif chemokine ligand 18(CCL18):a chemokine with immunosuppressive and pro-tumor functions[J].J Cell Commun Signal,2022,16(2):293-300.
12 温敏,刘莹莹,徐金锋,等.乳腺癌肿瘤微环境相关治疗靶点的研究进展[J].广东医学,2019,40(7):908-912.
13 姜懿纳,陈乃宏.CCL2/MCP-1在其相关疾病的机制研究[J].中国药理学通报,2016,32(12):1634-1638.
14 Meitei HT,Jadhav N,Lal G.CCR6-CCL20 axis as a therapeutic target for autoimmune diseases[J].Autoimmun Rev,2021,20(7):102846.
15 Nelson RT,Boyd J,Gladue RP,et al.Genomic organization of the CC chemokine MIP-3α/CCL20/LARC/Exodus/SCYA20,showing gene structure,splice variants,and chromosome localization[J].Genomics,2001,73(1):28-37.
16 Li L,Zhou J,Xu Y,et al.C-C chemokine receptor type 6 modulates the biological function of osteoblastogenesis by altering the expression levels of Osterix and OPG/RANKL[J].BioSci Trends,2021,15(4):240-248.
17 Fennen M,Weinhage T,Kracke V,et al.A myostatin-CCL20-CCR6 axis regulates Th17 cell recruitment to inflamed joints in experimental arthritis[J].Sci Rep,2021,11(1):1-12.
18 张娟.CCL20/CCR6轴和AEG-1对宫颈癌增殖侵袭的影响及机制研究[D].武汉:武汉大学,2017.
19 庄同田,易秀莉,亢盼,等.病毒感染对角质形成细胞CCL20表达的影响及其机制 [J].现代生物医学进展,2020,20(10):1840-1845.
20 Yu WQ,Ji NF,Gu CJ,et al.Coexpression of helios in Foxp3+ regulatory T cells and its role in human disease[J].Dis Markers,2021,2021:5574472.
21 Zhao X,Li Y,Wang X,et al.Synergistic association of Foxp3+ tumor infiltrating lymphocytes with CCL20 expressions with poor prognosis of primary breast cancer:a retrospective cohort study[J].Med,2019,98(50):e18403.
22 Chen B,Zhang D,Zhou J,et al.High CCR6/CCR7 expression and Foxp3+ Treg cell number are positively related to the progression of laryngeal squamous cell carcinoma[J].Oncol Rep,2013,30(3):1380-1390.
23 Zhou L,Li H,Zhang XX,et al.Rapamycin treated tol-dendritic cells derived from BM-MSCs reversed graft rejection in a rat liver transplantation model by inducing CD8+ CD45RC-Treg[J].Mol Immunol,2021,137:11-19.
24 Pakravan N,Abbasi A,Hassan ZM.Immunotherapy using oxygenated water and tumor-derived exosomes potentiates antitumor immune response and attenuates malignancy tendency in mice model of breast cancer[J].Oxid Med Cell Longev,2021,2021(3):1-15.
25 Chow MT,Luster AD.Chemokines in cancer[J].Cancer Immunol Res,2014,2(12):1125-1131.
26 Georgakopoulos-Soares I,Chartoumpekis DV,Kyriazopoulou V,et al.EMT factors and metabolic pathways in cancer[J].Front Oncol,2020,10:499.
27 Tran DD,Corsa CA,Biswas H,et al.Temporal and spatial cooperation of snail1 and twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence[J].Mol cancer Res,2011,9(12):1644-1657.
28 Martins LM,Dourado CSME,Campos-Verdes LM,et al.Expression of matrix metalloproteinase 2 and 9 in breast cancer and breast fibroadenoma:a randomized,double-blind study[J].Oncotarget,2019,10(64):6879-6884.
29 Huang H.Matrix metalloproteinase-9(MMP-9)as a cancer biomarker and MMP-9 biosensors:recent advances[J].Sens,2018,18(10):3249.
30 Muscella A,Vetrugno C,Marsigliante S.CCL20 promotes migration and invasiveness of human cancerous breast epithelial cells in primary culture[J].Mol Carcinog,2017,56(11):2461-2473.
31 Marsigliante S,Vetrugno C,Muscella A.CCL20 induces migration and proliferation on breast epithelial cells[J].J Cellular Physiol,2013,228(9):1873-1883.
32 Marsigliante S,Vetrugno C,Muscella A.Paracrine CCL20 loop induces epithelial‐mesenchymal transition in breast epithelial cells[J].Mol Carcinog,2016,55(7):1175-1186.
33 Moustakas A,Heldin CH.Induction of epithelial-mesenchymal transition by transforming growth factor β[J].Semin Cancer Biol,2012,22(5/6):446-454.
34 Li M,Li P,Zhang M,et al.Brucine suppresses breast cancer metastasis via inhibiting epithelial mesenchymal transition and matrix metalloproteinases expressions[J].Chin J Integr Med,2018,24(1):40-46.
35 牛明,于歌.Gankyrin促进乳腺癌增殖转移和肿瘤干细胞特征的研究[J].实用肿瘤学杂志,2020,34(6):518-523.
36 Chen W,Qin Y,Wang D,et al.CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer[J].PLoS Biol,2018,16(7):e2005869.
37 陈为龙.CCL20对三阴性乳腺癌化疗疗效的调控和分子机制研究[D].合肥:中国科学技术大学,2019.
38 Jayaraman S,Doucet M,Kominsky SL.CITED2 attenuates macrophage recruitment concordant with the downregulation of CCL20 in breast cancer cells[J].Oncol Lett,2018,15(1):871-878.
39 钱晨,彭柳莹,冯小可,等.雷公藤红素通过抑制趋化因子CCl4减少破骨细胞形成[J].辽宁中医杂志,2015,42(2):415-417.
40 谢玮.毛蕊异黄酮通过HOTAIR干预ER阴性乳腺癌细胞生长作用的研究[D].桂林:桂林医学院,2021.
41 Lee SK,Park KK,Kim HJ,et al.Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis[J].Sci Rep,2017,7(1):9610.
42 Kim KY,Baek A,Park YS,et al.Adipocyte culture medium stimulates invasiveness of MDA-MB-231 cell via CCL20 production.[J].Oncol Rep,2009,22(6):1497-1504.

[1]	YANG Zihan, XU Shouping, PANG Da. Characteristics of breast cancer metastases to outer triangle tissue and its influencing factors [J]. Journal of Practical Oncology, 2022, 36(3): 226-232.
[2]	HE Weidan, LI Zhigao. FSIP1 promotes migration and invasion of breast cancer cells and leads to poor prognosis of patients [J]. Journal of Practical Oncology, 2022, 36(3): 233-238.
[3]	YANG Shuya, LIU Wenhui, LUO Naixiang. Research status and application prospect of UCA1 in breast cancer [J]. Journal of Practical Oncology, 2022, 36(3): 263-267.
[4]	LIU Wanying, PANG Da. Research progress on the mechanism of metastasis in invasive micropapillary carcinoma of the breast [J]. Journal of Practical Oncology, 2022, 36(3): 268-272.
[5]	LIU Yu, YU Xingxin, GENG Zhida, CHEN Zhengliang, HUI Peng, LIANG Yingjian. The role of liver fibroblasts in the occurrence and development of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2022, 36(2): 167-172.
[6]	SUN Yuanyuan, ZHANG Ningzhi, CAO Mengru. The mechanism and treatment progress of breast cancer lung metastasis [J]. Journal of Practical Oncology, 2022, 36(2): 173-177.
[7]	HOU Jianxun, WANG Hongbin. Research progress on the influence of exosomes in the integration of breast cancer diagnosis and treatment [J]. Journal of Practical Oncology, 2022, 36(2): 178-182.
[8]	CHEN He, WANG Qiucheng, CHENG Wen. The application progress of automatic breast ultrasound diagnosis system in breast cancer [J]. Journal of Practical Oncology, 2022, 36(2): 193-196.
[9]	LI Weihua, ZHANG Guangfeng, MA Lili, HE Pin, WANG Wen, LI Dingfu. Construction of a breast cancer prognostic model based on metabolism-related genes in the TCGA database [J]. Journal of Practical Oncology, 2022, 36(1): 37-43.
[10]	DONG Lina, LIANG Tian, ZHANG Xian, ZHANG Guangmei. Research progress on tropism of ovarian cancer to fat-rich omentum organs [J]. Journal of Practical Oncology, 2022, 36(1): 54-58.
[11]	CAO Shiyu, JIANG Yongdong. The influence of gene expression,polygene detection and biomarkers on the prognosis of Luminal A-like breast cancer [J]. Journal of Practical Oncology, 2022, 36(1): 89-93.
[12]	LUO Bo, ZHANG Qu, ZHENG Hongmei, LIANG Xinjun, ZHOU Xiaomei, WU Xinhong. Efficacy and prognosis of SRT combined with lapatinib in the treatment of HER2-positive breast cancer brain metastasis [J]. Journal of Practical Oncology, 2021, 35(6): 523-528.
[13]	SHI Runze, LI Zhigao. Research progress of precision medical strategy for different subtypes of triple negative breast cancer [J]. Journal of Practical Oncology, 2021, 35(6): 529-533.
[14]	MU Guannan, MA Qiang. The role of NK cell polarization in endometrial cancer [J]. Journal of Practical Oncology, 2021, 35(6): 534-537.
[15]	LI Xiang, HU Yang, ZHANG Qingyuan. Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy [J]. Journal of Practical Oncology, 2021, 35(6): 568-571.

Research progress in the role of chemokine CCL20 in breast cancer microenvironment

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments